JPRN-UMIN000006139招募中2 期
Phase II Study of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy for Elderly Advanced Non-squamous and Non-small Cell Lung Cancer. - Phase II Study of PEM/CBDCA Followed by PEM for elderly Non-squamous and Non-small Cell Lung Cancer.
Tochigi Thoracic Oncology Research Organization0 个研究点目标入组 50 人开始时间: 2011年8月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with other clinically significant complications; for example, uncontrollable diabetes and hypertension. (2)Active severe infections. (3)Patients with symptomatic brain metastasis . (4)Patients with massive pleural or pericardial effusion. (5)With prior unapproved drugs or investigational new drugs. (6)Not appropriate to receive the folic acid and vitamin B12 formulation. (7)With peripheral nerves >= grade 2 at enrollment. (8)Continues to NSAIDs during this study. (9)Inappropriate patients for this study judged by the physicians.
研究者
相似试验
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEstudio en fase II de pemetrexed en combinación con cisplatino y cetuximab en el carcinoma de células escamosas de cabeza y cuello recurrente o metastásicoRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma de células escamosas de cabeza y cuello recurrente o metastásicoMedDRA version: 12.0Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaEUCTR2009-011611-21-ESEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-DEEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-GBEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 13.1Level: PTClassification code 10063569Term: Metastatic squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011611-21-BEEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - NDRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10063569EUCTR2009-011611-21-ITEli Lilly and Company Ltd.